Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.53M | $181M | $208M | $335M | $295M | $214M | $292M | $195M | $160M | $236M |
| Revenue growth | — | 11706.3% | 14.6% | 61.3% | -11.8% | -27.7% | 36.9% | -33.5% | -17.7% | 47.5% |
| Operating income | -$136M | -$76.7M | -$178M | -$286M | -$376M | -$265M | -$80.8M | -$46.3M | -$50.5M | $23.5M |
| Operating margin | -8889.9% | -42.3% | -85.8% | -85.5% | -127.5% | -124.2% | -27.6% | -23.8% | -31.5% | 9.9% |
| Net income | -$136M | -$73.7M | -$144M | -$280M | -$383M | -$283M | -$94.2M | -$51.9M | -$69.4M | -$5.34M |
| Net margin | -8843.5% | -40.7% | -69.1% | -83.5% | -129.9% | -132.4% | -32.2% | -26.7% | -43.3% | -2.3% |
| EPS (diluted) | -$3.60 | -$1.69 | -$2.47 | -$2.36 | -$2.77 | -$1.70 | -$0.52 | -$0.28 | -$0.33 | -$0.02 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $57.9M | -$56.2M | -$97.5M | -$257M | -$110M | -$253M | -$73.2M | -$23.4M | -$40.7M | $68.0M |
| Capital expenditures | $2.66M | $1.62M | $1.61M | $6.66M | $317K | $59.0K | $114K | $0.00 | $33.0K | $291K |
| Free cash flow | $55.2M | -$57.8M | -$99.1M | -$264M | -$111M | -$253M | -$73.3M | -$23.4M | -$40.7M | $67.7M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $187M | $70.2M | $105M | $147M | $229M | $150M | $90.5M | $42.9M | $51.9M | $185M |
| Total assets | $300M | $364M | $997M | $771M | $644M | $526M | $356M | $242M | $221M | $377M |
| Total liabilities | $232M | $242M | $361M | $376M | $397M | $449M | $351M | $272M | $270M | $344M |
| Long-term debt | — | — | — | $75.8M | $96.4M | $0.00 | $34.1M | $17.2M | $38.7M | $48.3M |
| Shareholders' equity | $68.1M | $123M | $636M | $395M | $248M | $74.0M | $5.23M | -$30.6M | -$49.2M | $32.6M |
| Retained earnings | -$297M | -$371M | -$514M | -$794M | -$1.18B | -$1.46B | -$1.56B | -$1.61B | -$1.68B | -$1.68B |
| Shares (wtd avg diluted) | 38.6M | 47.6M | 117M | 118M | 138M | 166M | 183M | 187M | 211M | 257M |
Every figure is extracted from Akebia Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.